Andrew J. Armstrong, MD
PARP inhibitors and immunotherapy agents continue to be investigated in the field of metastatic castration-resistant prostate cancer (mCRPC), and a focus must now be put on optimally selecting patients for these treatments, according to Andrew J. Armstrong, MD.
on Genitourinary Cancers. In an interview during the event, Armstrong discussed emerging treatments and techniques for precision medicine in mCRPC.
OncLive: Please provide an overview of your presentation.
I spoke about men with metastatic disease who have progressed on hormone therapy. Most of the approved drugs in prostate cancer are for these men. These include immunotherapy with sipuleucel-T (Provenge), hormonal therapy with abiraterone acetate, enzalutamide, chemotherapies, and radium-223 dichloride (Xofigo). I am focusing on what we call precision medicine, which is the ability to use biomarkers to help select patients for optimal therapy.
... to read the full story